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Abstract. Celiac disease (CD) is an autoimmune disease with estimated prevalence of 1% in European and North 
American population. All four components of CD autoimmunity are well known, such as: genetics, autoantigen, 
autoantibodies and the environmental triggers. Besides gastrointestinal manifestations, celiac disease has a wide array 
of extraintestinal symptoms and clinical signs. This article briefly summarizes celiac disease pathophysiology and 
association of celiac disease with other autoimmune diseases in children. It puts emphasis on possible protective role of 
gluten-free diet for the development of other autoimmune diseases in patients with celiac disease. 




Over the last few decades increased prevalence of many 
autoimmune diseases in the human population has been 
documented. Celiac disease (CD) is one of the most 
common autoimmune diseases in human population and 
the only disease with well-known environmental triggers 
of autoimmunity. Patients with one autoimmune disease 
are more susceptible to other autoimmune diseases. 
Coexistence of two or more autoimmune diseases in the 
same individual (autoimmune polyendocrine syndrome) 
has been published in literature [1]. 
At the beginning of the twentieth century, with the 
advent of the highly sensitive and highly specific 
serological screening tests for CD, large screening 
studies have been put into practice with the aim of 
identifying CD prevalence in general population and 
patients suffering from other autoimmune diseases. 
Celiac Disease 
CD is common, lifelong disease characterized by 
autoimmune damage of the small bowel mucosa. Recent 
epidemiological studies indicate that CD affects about 
1% of European and North American population [2,3]. 
Nowadays, all 4 components of CD autoimmunity are 
well known, such as: genetics, autoantigen, autoantibodies 
and the environmental triggers. Genetic predisposition 
is needed for CD occurrence. More than 95% of patients 
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are carriers of HLA-DQ2 haplotype (encoded by alleles 
DQA1 * 05 and DQB1 * 02). The rest of the patients 
are carriers of HLA-DQ8 (encoded by alleles DQA1 * 
03 and * DQB1- 0302). The role of the genes out of the 
HLA system was examined by GWARS (genome-wide 
association studies) [4,5]. More than 115 of these genes 
have been involved in the regulation of the innate and 
adaptive immune responses. However, the importance 
of each individual gene outside the HLA system for the 
development of CD is very small. 
The enzyme tissue transglutaminase (TG2) is located 
in lamina propria of small bowel mucosa. TG2 leads to 
deamination of glutamine residue of gliadin [6]. This 
reaction provides glutamine residue a negative charge and 
ability to bind to HLA DQ2 / DQ8  molecule on the 
antigen-presenting cells. TG2 participates in many 
physiological processes, such as extracellular matrix 
building, tissue reparation, signal mechanisms of 
receptors, cell proliferation, cell motility and endocytosis 
[7]. In addition to the small intestine, TG2 can also be 
found in the liver, muscles, and lymph nodes. 
Dietrich et al. (1997) were the first who discovered 
IgA antibodies against TG2 (Anti-TG2) in the sera of 
CD patients [8]. Deployment of tests based on Anti-
TG2 detection substantially improved the diagnostic 
accuracy of CD serologic testing. 
Development of CD requires food intake that 
contains gliadin fraction of gluten from wheat or similar 
prolamins from rye (secalins) and barley (hordeins). 
There are gliadin peptides which demonstrate two 
different effects on small bowel mucosa: toxic and 
immunostimulatory [9]. Alpha-gliadin peptides (31-43, 
44-55, 56-75) with toxic activity are responsible for the 
damage of the small bowel mucosa and initiation of the 
pathophysiological processes in CD. Peptides with 
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immunostimulatory effects initiate T helper 1 (Th1) 
response and secretion of interferon-γ. It is assumed that 
there are more than 50 gliadin peptides with this kind of 
effect. 
The pathophysiology of autoimmune damage of small 
bowel mucosa in CD is not completely understood. It 
encompasses complex interactions between the innate 
and adaptive immune response, triggered by ingestion 
of gluten. At the beginning of this process paracellular 
permeability of small bowel mucosa is increased for 
gluten peptides due to peptide induced CXCR3 activated 
upregulation of zonulin, an intestinal peptide involved 
in tight junctions control [10].  
Toxic gliadin peptides activate the innate immune 
system and increase production of interleukin 15 (IL-15) 
by epithelial and dendritic cells. IL-15 stimulates 
cytotoxic activity of intraepithelial lymphocytes through 
production of interferon γ (IFNγ) and stimulation of 
NKG2D cells. Activation of the adaptive immune 
response occurs after deamination of glutamine residues 
with TG2, their binding to dendritic cells and presentation 
to CD4 T lymphocytes followed by activation of the 
cellular (Th1) and humoral (Th2) immune response. Th1 
response leads to the IFNγ induced cell death of 
enterocytes. Th2 response causes differentiation of B 
lymphocytes into plasma cells capable of producing anti-
TG2 and antigliadin antibodies (AGA). It is not known 
whether anti-TG2 in a certain way influences the activity 
of the TG2. In addition to  Anti-TG2 other types of auto-
antibodies, such as antibodies against  actin and reticulin 
were detected  in CD [11]. 
CD may be manifested by typical (chronic diarrhea, 
loss of appetite, distended abdomen, malnutrition) and 
non-typical symptoms (stunted growth, refractory anemia, 
osteoporosis, unexplained hypertransaminasemia). The CD 
diagnosis is established on the basis of positive serology 
(anti-TG2 or anti-endomysial antibodies) and small bowel 
mucosa pathohistology. 
Celiac Disease and Other Autoimmune 
Diseases 
A group of autoimmune diseases is consisted of about 
80 different diseases affecting 5-8% of the human 
population [12]. Patients with a single autoimmune 
disease are at 25% risk of development of other 
autoimmune diseases [13]. Many studies in children have 
reported an association between CD and various 
autoimmune diseases. Common genetic background is one 
of the predisposing factors for this association [14,15]. 
There is a possibility that persistent activation by 
proinflammatory cytokines leads to the unmasking of other 
autoantigens (besides TG2) and the initiation of a new 
autoimmune attack. Recent studies demonstrated that gut 
microflora plays an important role, not only in shaping the 
immune responses, but also in the development of 
autoimmunity [16].  
Italian authors have found an increased frequency of 
organ-specific antibodies in CD patients [17]. Titer of 
antibodies significantly decreased following the 
commencement of the gluten-free diet (GFD). On the 
basis of this, they hypothesized that GFD may prevent 
the occurrence of other autoimmune diseases. However, 
subsequent studies have not confirmed the protective 
role of GFD [18,19]. Development of other autoimmune 
disease is more likely if the CD is diagnosed in young 
individuals with positive family history of CD [20]. 
Celiac Disease and Diabetes Mellitus Type 1   
Diabetes mellitus type 1 (DMT1) is one of the most 
common chronic diseases in children with increasing 
annual prevalence from 3% to 4% [21]. Numerous 
screening studies conducted around the world showed 
the increased prevalence of CD (2.4% -16.4%) in 
patients with DMT1 [22].  The only screening study of 
this type in Serbia revealed the CD prevalence of  
5.79% in children and adolescents with  DMT1 [23]. 
DMT1 patients with CD can be asymptomatic (60%-
70% of patients) or have classical CD symptoms. It 
should be kept in mind that positive titer of anti-TG2 in 
DMT1 patients does not always mean that they have 
CD. In a number of serologically positive DMT1 
patients who do not have symptoms of the CD, anti-
TG2 disappeared spontaneously, even though they 
continued to use gluten containing food. In these 
children anti-TG2 titer levels are usually slightly lower 
than in  asymptomatic CD patients. 
Some studies suggest that patients with newly 
diagnosed DMT1 and CD have frequent hypoglycemic 
episodes, higher average value of glycosylated 
hemoglobin, and reduced bone mineral density [24-26].  
Conflicting evidence exist as to whether a GFD 
significantly improves glycemic control in DMT1 patients  
[24,27,28]. 
Children and adolescents with DMT1 and CD are 
prone to vascular complications later in life. CD is 
regarded as an independent risk factor for retinopathy 
and nephropathy in patients with DMT1 [29].   
The International Society for Pediatric and Adolescent 
Diabetes (ISPAD) recommended serological screening 
for CD in all children with DMT1 at the time of DMT1 
diagnosis and every  1-2 years thereafter [30] because 
positive titer of Anti-TG2 can be found many years after 
the beginning of DMT1. 
Celiac Disease and Autoimmune Thyroid 
Disease 
Many screening studies in children with autoimmune 
thyroid disease (Hashimoto's thyroiditis, Graves' disease) 
have found an increased prevalence of CD (2.3-7.9%) 
[31]. CD has been  more commonly found in autoimmune 
thyroiditis than in Graves' disease. Serologic CD 
screening is recommended in children with autoimmune 
thyroid disease by the European Society for Pediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN)  
[32]. 
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Investigations were carried out in the opposite 
direction as well, with the aim of determining the 
prevalence of autoimmune thyroid disease in children 
with CD. In one Italian study autoimmune thyroid 
disease was found in 26.2% of pediatric patients with 
CD [33]. Thyroid dysfunction in CD has a negative 
impact not only on growth, metabolism of proteins and 
cholesterol, but also on cognitive function and fertility.  
Celiac Disease and Autoimmune Hepatitis 
In case of elevated transaminases in children with CD, 
autoimmune hepatitis and non-specific reactive hepatitis 
(celiac hepatitis) should be considered. Autoimmune 
hepatitis (AIH) is a chronic disease in genetically 
predisposed individuals in whom the autoimmunity is 
directed toward liver antigens. Pediatric surveys have 
reported a wide prevalence of CD in AIH in a range 
from 3.6% to 12% [34]. Although there are still no 
recommendations for routine serological CD screening 
in patients with AIH, the association between these two 
diseases should be considered if one of them is 
diagnosed. Rare cases of CD associated with other 
autoimmune liver diseases such as primary sclerosing 
cholangitis (PSC) and "overlap" syndrome (AIH / PSC) 
were described in children [35,36].  
Celiac hepatitis is found in 26-57% of children with 
CD [37,38]. It is manifested by the elevation of 
transaminases without any symptoms of liver disease. 
The increased intestinal permeability in CD may ease 
the entry of toxins, antigens, antibodies and cytokines to 
the portal system leading to hepatocytes function 
impairment [34]. In most cases (70-100%) transaminase 
levels are normalized within a year on GFD. All patients 
with unexplained hypertransaminasemia should be 
serologically tested for CD. 
Celiac Disease and Dermatological Diseases 
CD may be associated with various skin manifestations, 
such as dermatitis herpetiformis (DH), psoriasis, alopecia 
areata and vitiligo [39-41]. DH is most frequently found 
in adolescents, young and middle-aged adults. All 
patients with DH have some forms of enteropathy that 
can be found in CD. In 10-20% of DH patients, in 
addition to rash, there is a typical clinical picture of a CD 
while in the rest of 80-90% atypical or "silent" CD 
clinical forms are seen. GFD is standard treatment for DH 
with excellent clinical response. Since the reintroduction 
of gluten in a diet after clinical recovery on GFD triggers 
relapses of cutaneous and intestinal lesions, DH is 
regarded as skin manifestation of CD [39]. 
Celiac disease and rheumatological diseases 
CD is found in in 1.5% -2.8% of children with juvenile 
rheumatoid arthritis [42,43]. The prevalence of CD is less 
studied in other rheumatological diseases in pediatric 
population. Studies examining positive effect of GFD on 
arthritis were not conducted in children, while in adults 
they are very rare. Sjogren's syndrome is considered the 
most common rheumatological disease associated with 
CD (in 12% -14.4% cases) in adults [44,45]. 
Conclusion 
CD may be associated with many diseases of autoimmune 
origin. Currently, there are recommendations of  
international societies such as ISPAD and ESPGHAN for 
CD serological screening only in children with T1DM 
and autoimmune thyroid disease. Future studies with the 
involvement of large number of children, including a 
cost-benefit analysis, are going to show whether CD 
screening for children with other autoimmune diseases 
will be justified. Despite a very promising hypothesis, 
there is still no scientifically based evidence that GFD has 
prophylactic effect on the development of other 
autoimmune diseases in patients with CD. 
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